AbbVie Pty Ltd

Vyalev (foslevodopa and foscarbidopa) was approved to treat idiopathic Parkinson’s disease with severe motor fluctuations despite optimised alternative pharmacological treatment.

Rinvoq (upadacitinib) was approved for the treatment of active non-radiographic axial spondyloarthritis in adults.

Aquipta (atogepant) has been approved for the prophylaxis of migraine in adults who have at least four migraine days per month

AusPAR for RINVOQ (Upadacitinib) for treatment of atopic dermatitis in patients aged 12 years and above.

AusPAR for Maviret (glecaprevir /pibrentasvir) for the treatment of adult and paediatric patients with chronic hepatitis C virus.

New AusPAR for Venclexta (venetoclax) for acute myeloid leukaemia indication, provisional to full registration.

Australian Public Assessment Report for Upadacitinib

Australian Public Assessment Report for Venetoclax 

Australian Public Assessment Report for Venetoclax

Australian Public Assessment Report for Upadacitinib